{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:31:45Z","timestamp":1791189105145,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T00:00:00Z","timestamp":1348531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00415-012-6669-1","type":"journal-article","created":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T06:19:16Z","timestamp":1348467556000},"page":"521-527","source":"Crossref","is-referenced-by-count":28,"title":["Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"260","author":[{"given":"Ashok","family":"Sriram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert E.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhar","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D.","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon L.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus R.","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,25]]},"reference":[{"issue":"9","key":"6669_CR1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1212\/01.wnl.0000405146.06300.91","volume":"77","author":"M Hoehn","year":"2011","unstructured":"Hoehn M, Yahr M (2011) Parkinsonism: onset, progression, and mortality. Neurology 77(9):874. doi: 10.1212\/01.wnl.0000405146.06300.91","journal-title":"Neurology"},{"issue":"3","key":"6669_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181\u2013184. doi: 10.1136\/jnnp.55.3.181","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"6669_CR3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/mds.22875","volume":"25","author":"YJ Zhao","year":"2010","unstructured":"Zhao YJ, Wee HL, Chan Y, Seah SH, Au WL, Lau PN et al (2010) Progression of Parkinson\u2019s disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord 25(6):710\u2013716. doi: 10.1002\/mds.22875","journal-title":"Mov Disord"},{"issue":"2","key":"6669_CR4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0733-8619(18)30213-5","volume":"10","author":"MM Hoehn","year":"1992","unstructured":"Hoehn MM (1992) The natural history of Parkinson\u2019s disease in the pre-levodopa and post-levodopa eras. Neurol Clin 10(2):331\u2013339","journal-title":"Neurol Clin"},{"key":"6669_CR5","first-page":"S13","volume":"55","author":"JA Obeso","year":"2000","unstructured":"Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW (2000) The evolution and origin of motor complications in Parkinson\u2019s disease. Neurology 55:S13\u2013S20","journal-title":"Neurology"},{"issue":"4","key":"6669_CR6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","volume":"68","author":"G Giovannoni","year":"2000","unstructured":"Giovannoni G, O\u2019Sullivan JD, Turner K, Manson AJ, Lees AJL (2000) Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68(4):423\u2013428. doi: 10.1136\/jnnp.68.4.423","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"6669_CR7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/jnnp.69.4.566a","volume":"69","author":"R Cantello","year":"2000","unstructured":"Cantello R (2000) Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 69(4):566\u2013567. doi: 10.1136\/jnnp.69.4.566a","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"6669_CR8","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/mds.22505","volume":"24","author":"AH Evans","year":"2009","unstructured":"Evans AH, Strafella AP, Weintraub D, Stacy M (2009) Impulsive and compulsive behaviors in Parkinson\u2019s disease. Mov Disord 24(11):1561\u20131570. doi: 10.1002\/mds.22505","journal-title":"Mov Disord"},{"key":"6669_CR9","author":"N Limotai","year":"2011","unstructured":"Limotai N, Oyama G, Go C, Bernal O, Ong T, Moum SJ et al (2011) Addiction-like manifestations and Parkinson\u2019s disease: a large single center 9-year experience. Int J Neurosci. doi: 10.3109\/00207454.2011.633722","journal-title":"Int J Neurosci"},{"issue":"12","key":"6669_CR10","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","volume":"26","author":"E Bondon-Guitton","year":"2011","unstructured":"Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc J (2011) Drug-induced parkinsonism: a review of 17\u00a0years\u2019 experience in a regional pharmacovigilance center in France. Mov Disord 26(12):2226\u20132231. doi: 10.1002\/mds.23828","journal-title":"Mov Disord"},{"key":"6669_CR11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1212\/01.WNL.0000121228.32913.00","volume":"62","author":"K Easterford","year":"2004","unstructured":"Easterford K, Clough P, Kellett M et al (2004) Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 62:1435\u20131437","journal-title":"Neurology"},{"issue":"6","key":"6669_CR12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.amjopharm.2011.09.002","volume":"9","author":"F Mahmoud","year":"2011","unstructured":"Mahmoud F, Tampi RR (2011) Valproic Acid\u2013Induced parkinsonism in the elderly: a comprehensive review of the literature. Am J Geriatric Pharmacother 9(6):405\u2013412. doi: 10.1016\/j.amjopharm.2011.09.002","journal-title":"Am J Geriatric Pharmacother"},{"key":"6669_CR13","doi-asserted-by":"crossref","unstructured":"Kummer A, Maia DP, Salgado JV, Cardoso FEC, Teixeira AL (2006) Dopamine dysregulation syndrome in Parkinson\u2019s disease: case report. Arquivos De Neuro-Psiquiatria 64(4):1019\u20131022","DOI":"10.1590\/S0004-282X2006000600026"},{"issue":"12","key":"6669_CR14","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/mds.22652","volume":"24","author":"W Gerschlager","year":"2009","unstructured":"Gerschlager W, Bloem BR (2009) Managing pathological gambling in Parkinson\u2019s disease with enteral levodopa\/carbidopa infusions. Mov Disord 24(12):1858\u20131860. doi: 10.1002\/mds.22652","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"6669_CR15","first-page":"271","volume":"310","author":"K Regina","year":"2011","unstructured":"Regina K (2011) Dopaminergic dysregulation syndrome in Parkinson\u2019s disease. J Neurol Sci 310(1\u20132):271\u2013275. doi: 10.1016\/j.jns.2011.07.012","journal-title":"J Neurol Sci"},{"issue":"6","key":"6669_CR16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.parkreldis.2006.07.011","volume":"13","author":"F Bandini","year":"2007","unstructured":"Bandini F, Primavera A, Pizzorno M, Cocito L (2007) Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson\u2019s disease. Parkinsonism Relat Disord 13(6):369\u2013371. doi: 10.1016\/j.parkreldis.2006.07.011","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"6669_CR17","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/mds.20501","volume":"20","author":"T Witjas","year":"2005","unstructured":"Witjas T, Baunez C, Henry JM, Delfini M, Regis J, Cherif AA et al (2005) Addiction in Parkinson\u2019s disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 20(8):1052\u20131055. doi: 10.1002\/mds.20501","journal-title":"Mov Disord"},{"key":"6669_CR18","doi-asserted-by":"crossref","unstructured":"De la Casa-Fages B, Grandas F (2012) Dopamine dysregulation syndrome after deep brain stimulation of the subthalamic nucleus in Parkinson\u2019s disease. J Neurol Sci. doi: 10.1016\/j.jns.2011.08.014","DOI":"10.1016\/j.jns.2011.08.014"},{"issue":"1","key":"6669_CR19","doi-asserted-by":"crossref","first-page":"e29768","DOI":"10.1371\/journal.pone.0029768","volume":"7","author":"SJ Moum","year":"2012","unstructured":"Moum SJ, Price CC, Limotai N, Oyama G, Ward H et al (2012) Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 7(1):e29768. doi: 10.1371\/journal.pone.0029768","journal-title":"PLoS One"},{"key":"6669_CR20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E (2002) Pharmacological and therapeutic properties of valproate. A summary after 35\u00a0years of clinical experience. CNS Drugs 16:695\u2013714","journal-title":"CNS Drugs"},{"key":"6669_CR21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2710.2005.00671.x","volume":"30","author":"GM Peterson","year":"2005","unstructured":"Peterson GM, Maunton M (2005) Valproate: a simple chemical with so much to offer. J Clin Pharm Ther 30:417\u2013421","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"6669_CR22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/archneur.1995.00540270077022","volume":"52","author":"NT Mathew","year":"1995","unstructured":"Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S et al (1995) Migraine prophylaxis with divalproex. Arch Neurol 52(3):281\u2013286. doi: 10.1001\/archneur.1995.00540270077022","journal-title":"Arch Neurol"},{"issue":"6","key":"6669_CR23","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/j.1471-4159.1980.tb11250.x","volume":"34","author":"W L\u00f6scher","year":"1980","unstructured":"L\u00f6scher W (1980) Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake and metabolism of GABA. J Neurochem 34(6):1603\u20131608. doi: 10.1111\/j.1471-4159.1980.tb11250.x","journal-title":"J Neurochem"},{"issue":"3","key":"6669_CR24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0006-8993(79)90975-2","volume":"170","author":"RL Macdonald","year":"1979","unstructured":"Macdonald RL, Bergey GK (1979) Valproic acid augments GABA-mediated postsynaptic inhibition in cultured mammalian neurons. Brain Res 170(3):558\u2013562. doi: 10.1016\/0006-8993(79)90975-2","journal-title":"Brain Res"},{"issue":"10","key":"6669_CR25","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0028-3908(05)80002-4","volume":"33","author":"LM Tian","year":"1994","unstructured":"Tian LM, Alkadhi KA (1994) Valproic acid inhibits the depolarizing rectification in neurons of rat amygdala. Neuropharmacology 33(10):1131\u20131138","journal-title":"Neuropharmacology"},{"issue":"3","key":"6669_CR26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0022-3565(25)24966-7","volume":"237","author":"MJ McLean","year":"1986","unstructured":"McLean MJ, Macdonald RL (1986) Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 237(3):1001\u20131011","journal-title":"J Pharmacol Exp Ther"},{"key":"6669_CR27","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/0306-3623(92)90313-9","volume":"23","author":"G Sarro De","year":"1992","unstructured":"De Sarro G, Ascioti C, di Paola ED, Vidal MJ, De Sarro A (1992) Effects of antiepileptic drugs, calcium channel blockers and other compounds on seizures induced by activation of voltage-dependent L calcium channel in DBA\/2 mice. Gen Pharmacol 23:1205\u20131216","journal-title":"Gen Pharmacol"},{"key":"6669_CR28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1021\/tx0502241","volume":"19","author":"D Eikel","year":"2006","unstructured":"Eikel D, Lampen A, Nau H (2006) Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 19:272\u2013278","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"6669_CR29","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/dmd.105.008078","volume":"34","author":"D Eikel","year":"2006","unstructured":"Eikel D, Hoffmann K, Zoll K, Lampen A, Nau H (2006) S-2-pentyl-4-pentynoic hydroxamic and its metabolite S-2 metabolite S-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides. Drug Metab Dispos 34(4):612\u2013620. doi: 10.1124\/dmd.105.008078","journal-title":"Drug Metab Dispos"},{"issue":"45","key":"6669_CR30","doi-asserted-by":"crossref","first-page":"16423","DOI":"10.1523\/JNEUROSCI.2506-11.2011","volume":"31","author":"K T\u00f6llner","year":"2011","unstructured":"T\u00f6llner K, Wolf S, L\u00f6scher W, Gernert M (2011) The anticonvulsant response to valproate in kindled rats is correlated with its effect on neuronal firing in the substantia nigra pars reticulata: a new mechanism of pharmacoresistance. J Neurosci 31(45):16423\u201316434. doi: 10.1523\/JNEUROSCI.2506-11.2011","journal-title":"J Neurosci"},{"key":"6669_CR31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","volume":"16","author":"W L\u00f6scher","year":"2002","unstructured":"L\u00f6scher W (2002) Basic pharmacology of valproate: a review after 35\u00a0years of clinical use for the treatment of epilepsy. CNS Drugs 16:669\u2013694","journal-title":"CNS Drugs"},{"issue":"2","key":"6669_CR32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.brainresrev.2009.06.003","volume":"61","author":"SI Rapoport","year":"2009","unstructured":"Rapoport SI, Basselin M, Kim H, Rao JS (2009) Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 61(2):185\u2013209. doi: 10.1016\/j.brainresrev.2009.06.003","journal-title":"Brain Res Rev"},{"issue":"8","key":"6669_CR33","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.neuropharm.2011.07.025","volume":"61","author":"E Ramadan","year":"2011","unstructured":"Ramadan E, Basselin M, Taha AY, Cheon Y, Chang L, Chen M et al (2011) Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in rats. Neuropharmacology 61(8):1256\u20131264. doi: 10.1016\/j.neuropharm.2011.07.025","journal-title":"Neuropharmacology"},{"issue":"7\u20138","key":"6669_CR34","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.neuropharm.2010.10.021","volume":"60","author":"A Guidotti","year":"2011","unstructured":"Guidotti A, Auta J, Chen Y, Davis JM, Dong E, Gavin DP et al (2011) Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 60(7\u20138):1007\u20131016. doi: 10.1016\/j.neuropharm.2010.10.021","journal-title":"Neuropharmacology"},{"issue":"2","key":"6669_CR35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jpsychires.2010.05.011","volume":"45","author":"LK Jornada","year":"2011","unstructured":"Jornada LK, Valvassori SS, Steckert AV, Moretti M, Mina F, Ferreira CL et al (2011) Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J Psychiatr Res 45(2):162\u2013168. doi: 10.1016\/j.jpsychires.2010.05.011","journal-title":"J Psychiatr Res"},{"issue":"5","key":"6669_CR36","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ana.20822","volume":"59","author":"AH Evans","year":"2006","unstructured":"Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M et al (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59(5):852\u2013858. doi: 10.1002\/ana.20822","journal-title":"Ann Neurol"},{"issue":"7","key":"6669_CR37","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/mds.22898","volume":"25","author":"AH Evans","year":"2010","unstructured":"Evans AH, Lawrence AD, Cresswell SA, Katzenschlager R, Lees AJ (2010) Compulsive use of dopaminergic drug therapy in Parkinson\u2019s disease: reward and anti-reward. Mov Disord 25(7):867\u2013876. doi: 10.1002\/mds.22898","journal-title":"Mov Disord"},{"issue":"10","key":"6669_CR38","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(03)00529-5","volume":"2","author":"AD Lawrence","year":"2003","unstructured":"Lawrence AD, Evans AH, Lees AJ (2003) Compulsive use of dopamine replacement therapy in Parkinson\u2019s disease: reward systems gone awry? Lancet Neurol 2(10):595\u2013604. doi: 10.1016\/S1474-4422(03)00529-5","journal-title":"Lancet Neurol"},{"issue":"6","key":"6669_CR39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ana.22356","volume":"69","author":"V Voon","year":"2011","unstructured":"Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J et al (2011) Impulse control disorders in Parkinson disease: a multicenter case control study. Ann Neurol 69(6):986\u2013996. doi: 10.1002\/ana.22356","journal-title":"Ann Neurol"},{"issue":"5","key":"6669_CR40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.parkreldis.2011.03.003","volume":"17","author":"CW Hicks","year":"2011","unstructured":"Hicks CW, Pandya MM, Itin I, Fernandez HH (2011) Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 17(5):379\u2013381. doi: 10.1016\/j.parkreldis.2011.03.003","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"6669_CR41","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/brain\/awr080","volume":"134","author":"V Voon","year":"2011","unstructured":"Voon V, Gao J, Brezing C, Symmonds M, Ekanayake V, Fernandez H et al (2011) Dopamine agonists and risk: impulse control disorders in Parkinson\u2019s disease. Brain 134(5):1438\u20131446. doi: 10.1093\/brain\/awr080","journal-title":"Brain"},{"key":"6669_CR42","first-page":"603631","volume":"2012","author":"BJ Kelley","year":"2012","unstructured":"Kelley BJ, Duker AP, Chiu P (2012) Dopamine agonists and pathologic behaviors. Parkinson\u2019s Dis 2012:603631. doi: 10.1155\/2012\/603631","journal-title":"Parkinson\u2019s Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-012-6669-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-012-6669-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-012-6669-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:31:50Z","timestamp":1744187510000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-012-6669-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,25]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["6669"],"URL":"https:\/\/doi.org\/10.1007\/s00415-012-6669-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,25]]}}}